ROCKWELL MEDICAL, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ROCKWELL MEDICAL, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.70M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.48M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.70M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.08M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($2.42M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.73M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $2.84M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.58M) | Mar 17, 2020 |
| FY2017 | Dec 31, 2017 | ($1.22M) | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $1.07M | Mar 15, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.31M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($480.0K) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($8.44M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($18.68M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($32.67M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($30.89M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($34.13M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($32.13M) | Mar 17, 2020 |
| FY2017 | Dec 31, 2017 | ($9.04M) | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | ($5.06M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.69M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $608.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($6.67M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($16.78M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($30.34M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($28.42M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($34.53M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($32.44M) | Mar 17, 2020 |
| FY2017 | Dec 31, 2017 | ($9.22M) | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | ($5.03M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.11M | Mar 20, 2025 |
| FY2018 | Dec 31, 2018 | $5.64M | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | $2.13M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $1.30M | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $1.68M | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $1.21M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $1.20M | Mar 15, 2018 |
| FY2017 | Sep 30, 2016 | $1.26M | Mar 15, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $23.08M | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | $5.87M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $4.79M | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $6.54M | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $6.10M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $6.05M | Mar 15, 2018 |
| FY2017 | Sep 30, 2016 | $5.07M | Mar 15, 2018 |
| FY2017 | Jun 30, 2016 | $5.01M | Mar 15, 2018 |
| FY2017 | Mar 31, 2016 | $4.99M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $6.09M | Mar 15, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($659.0K) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.20M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.41M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($16.93M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($33.53M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($29.64M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($27.25M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($20.42M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($21.11M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($12.45M) | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.15M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $59.21M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $52.17M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $46.64M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $48.57M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $77.75M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $44.32M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $52.56M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $58.78M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $83.15M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.16M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $26.62M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $30.88M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $32.53M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $46.04M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $43.58M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $24.00M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $25.28M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $25.87M | Mar 18, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.98M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $32.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $21.29M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $14.11M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.54M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $34.17M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $20.32M | Apr 8, 2022 |
| FY2020 | Dec 31, 2018 | $27.28M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $32.91M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | $52.96M | Mar 18, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $921.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $921.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $921.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $921.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $921.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $921.0K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $921.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $920.7K | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $920.7K | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $920.7K | Mar 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($402.99M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($397.68M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($397.20M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($388.76M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($370.08M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($337.41M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($306.52M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($272.39M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($240.26M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($214.34M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.71M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.66M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.98M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.10M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $13.28M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $48.68M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $11.80M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $22.71M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $8.41M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $17.18M | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 8, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | 0 | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | 0 | Mar 15, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 8, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | 0 | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | 0 | Mar 15, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.41M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 34.06M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 29.13M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 12.16M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 8.54M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 93.57M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | 65.38M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 57.03M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 51.77M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 51.53M | Mar 15, 2018 |